Welcome to our dedicated page for Alpha Cognition SEC filings (Ticker: ACOG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alpha Cognition Inc. filings document the regulatory record of a British Columbia biopharmaceutical issuer with no-par-value common shares listed on Nasdaq under ACOG. The disclosures identify the company as an emerging growth company and cover formal reporting around ZUNVEYL commercialization, financial results, operational updates, and capital and compensation arrangements.
Recent Form 8-K filings address results of operations, Regulation FD disclosures, board appointments and departures, equity awards under incentive plans, and material agreements tied to legacy Memogain asset and license obligations. Proxy materials describe annual general meeting matters, including director elections, board size, auditor appointment, shareholder voting procedures, and accompanying annual financial statement materials.
Alpha Cognition Inc. (ACOG) reported that large shareholder Opaleye Management Inc., through entities it manages, purchased a total of 123,918 shares of Alpha Cognition common stock in open-market or private transactions on September 14–16, 2026. The purchases were made indirectly via Opaleye, L.P. and a separately managed account, and Opaleye Management Inc. disclaims beneficial ownership beyond its pecuniary interest.
Alpha Cognition Inc. (ACOG) director Robert James Wills purchased 10,000 Common Shares on 2026-08-21 in a purchase in open market or private transaction at a price of $9.62 per share. Following this transaction, he directly owns 32,241 Common Shares of Alpha Cognition Inc.
Alpha Cognition Inc. reported strong top-line growth in the quarter ended June 30, 2026 as its Alzheimer’s drug ZUNVEYL scaled. Total revenue rose to $6.1 million for the quarter and $9.6 million year-to-date, driven by higher prescription volumes and a higher wholesale acquisition cost of $869.36 per month.
Gross profit grew to $5.7 million in the quarter, but the company remains unprofitable as it invests in commercialization and development. Net loss was $8.8 million for the quarter and $15.3 million for the first half of 2026. Operating expenses reached $13.5 million in Q2, led by selling, general and administrative spending of $11.4 million and research and development of $2.0 million.
Cash and cash equivalents were $41.4 million against current liabilities of $6.4 million, with operating cash outflow of $18.7 million in the first half. Management believes current cash will fund operations for at least 12 months but expects to seek additional capital, including use of a $75 million at-the-market facility that has not yet been utilized.
Alpha Cognition Inc. reported that Opaleye Management Inc., a ten percent owner, through Opaleye, L.P. purchased 50,000 shares of common stock on August 3, 2026 at $8.00 per share and 2,900 shares on July 31, 2026 at a weighted average price of $7.9226 per share, with trades between $7.855 and $7.95. Opaleye Management also reported 100,000 shares held indirectly through a separately managed account and disclaims beneficial ownership of the reported shares except to the extent of its pecuniary interest.
Opaleye Management Inc., a more than ten percent owner of Alpha Cognition Inc., reported an indirect purchase of 130 shares of common stock at $7.90 per share on July 24, 2026, through Opaleye, L.P., bringing that fund's reported holdings to 2,995,323 shares.
Opaleye Management also reports indirect holdings of 100,000 shares in a separately managed account and disclaims beneficial ownership beyond its pecuniary interest.
Opaleye Management Inc., a ten percent owner of Alpha Cognition Inc., indirectly purchased a total of 200,086 common shares on July 22–23, 2026 for Opaleye, L.P. and a separately managed account at weighted average prices of $7.8337 and $7.7953 per share, within disclosed ranges of $7.75–$7.90 and $7.655–$7.8667. Opaleye Management may be deemed to beneficially own these securities but disclaims beneficial ownership except to the extent of its pecuniary interest.
Alpha Cognition Inc. is reported to have a significant shareholder group led by Opaleye Management Inc., Opaleye, L.P., and James Silverman, which together report beneficial ownership of 3,095,193 shares of common stock. This represents 14.22% of Alpha Cognition’s common shares, based on 21,774,104 shares outstanding as referenced in a Form 10-Q filed on May 14, 2026.
The reporting persons indicate no sole voting or dispositive power over the shares, but shared voting and shared dispositive power over 3,095,193 shares, including shares held in a managed account advised by Opaleye Management Inc. The filing notes that it should not be construed as an admission that any reporting person is the beneficial owner of the shares for purposes of Section 13 of the Exchange Act.
Opaleye Management Inc., a more than ten percent holder of Alpha Cognition Inc., reported open‑market purchases of the company’s common stock. Through Opaleye, L.P., it bought 152,336 shares on June 26, 2026 at a weighted average price of $6.4017 per share, and 197 shares on June 25, 2026 at $6.50 per share. After these trades, Opaleye, L.P. held 2,805,107 shares indirectly, while a separately managed account held 90,000 shares. The filing notes these prices reflect multiple trades between $6.335 and $6.50 and that Opaleye Management may be deemed to beneficially own these securities but disclaims beneficial ownership except to the extent of its pecuniary interest.
Alpha Cognition Inc. has an amended Schedule 13G/A showing that Opaleye Management Inc., Opaleye, L.P. and James Silverman collectively report beneficial ownership of 2,895,107 shares, representing 13.30% of the company's common stock. The filing states these shares are held directly by the fund and in a managed account over which the adviser and Mr. Silverman have shared voting and dispositive power. The percentage is calculated using 21,774,104 shares outstanding as reported in the company’s Form 10-Q filed 05/14/2026. The amendment is signed by James Silverman on behalf of the reporting persons.
Alpha Cognition Inc. reported results from its 2026 annual meeting and a board leadership change. The board appointed Dr. Robert Wills as non-executive Chair, filling the vacancy created when Len Mertz did not stand for re-election.
As of the April 24, 2026 record date, 21,774,104 common shares and 316,655 preferred shares were issued, outstanding and entitled to vote. At the meeting, 10,535,277 shares were represented in person or by proxy, establishing a quorum. Shareholders approved setting the board size at six directors, elected all six nominees, and ratified CBIZ CPAs P.C. as the company’s independent registered public accounting firm for the ensuing year.